Page last updated: 2024-10-25

debrisoquin and Kidney Diseases

debrisoquin has been researched along with Kidney Diseases in 3 studies

Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.

Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.

Research Excerpts

ExcerptRelevanceReference
"Flecainide disposition was altered in the PMs."1.28The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. ( Beckmann, J; Eichelbaum, M; Gross, AS; Gundert-Remy, U; Hertrampf, R; Mikus, G, 1989)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19902 (66.67)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dorne, JL1
Walton, K1
Slob, W1
Renwick, AG1
Mikus, G1
Gross, AS1
Beckmann, J1
Hertrampf, R1
Gundert-Remy, U1
Eichelbaum, M1
Hamilton, M1

Other Studies

3 other studies available for debrisoquin and Kidney Diseases

ArticleYear
Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2002, Volume: 40, Issue:11

    Topics: Adult; Aged; Aging; Benzhydryl Compounds; Cresols; Cyclohexanols; Cytochrome P-450 CYP2D6; Debrisoqu

2002
The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide.
    Clinical pharmacology and therapeutics, 1989, Volume: 45, Issue:5

    Topics: Adult; Analysis of Variance; Chromatography, High Pressure Liquid; Debrisoquin; Female; Flecainide;

1989
Hypertension.
    The Practitioner, 1974, Volume: 213, Issue:1276 SPEC

    Topics: Adrenergic beta-Antagonists; Aortic Diseases; Benzothiadiazines; Brain Diseases; Cerebrovascular Dis

1974